Ignite Creation Date:
2024-05-06 @ 10:21 AM
Last Modification Date:
2024-10-26 @ 12:28 PM
Study NCT ID:
NCT03230318
Status:
COMPLETED
Last Update Posted:
2023-12-19
First Post:
2017-07-24
Brief Title:
Derazantinib in Subjects With FGFR2 Gene Fusion- Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
Sponsor:
Basilea Pharmaceutica
Organization:
Basilea Pharmaceutica
Organization Data
Organization:
Basilea Pharmaceutica
Class:
INDUSTRY
Study ID:
DZB-CS-301
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Basilea Pharmaceutica
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None